Thursday, December 10, 2020 – Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated
OSLO, Norway and CHENGDU, China. 03 November,2020— CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will fund the development of the protein-based S-Trimer COVID-19 vaccine candidate
London 25 September 2018 — Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok